Urinary S-Phenylmercapturic Acid

Background

S-Phenylmercapturic acid (SPMA) is a specific and widely recognized biomarker used to assess exposure to benzene, a known human carcinogen.^[1]Benzene is a ubiquitous environmental pollutant originating from various sources, including tobacco smoke, vehicle exhaust, and industrial emissions. Due to its established link to adverse health outcomes, particularly leukemia, and potential involvement in lung cancer etiology, monitoring benzene exposure is critical.^[1] Urinary SPMA levels reflect the internal dose of benzene absorbed by the body, making it a valuable tool in environmental health and toxicology studies for assessing exposure to this harmful chemical.

Biological Basis

Upon exposure, benzene undergoes metabolic transformation in the body. A key step involves its oxidation to benzene oxide, a reactive intermediate.^[1] This epoxide is subsequently detoxified through conjugation with glutathione, a process primarily catalyzed by glutathione S-transferase enzymes, particularly GSTT1 (Glutathione S-transferase theta 1).^[1] The resulting conjugate is then further processed and ultimately excreted in urine as S-phenylmercapturic acid. Genetic variations, such as deletions in the GSTT1 and GSTM1 (Glutathione S-transferase mu 1) genes, can significantly influence the efficiency of this detoxification pathway and, consequently, the levels of urinary SPMA.^[1] For instance, individuals with a GSTT1 null genotype may exhibit lower urinary SPMA levels despite higher benzene exposure, as less benzene oxide is conjugated and excreted via this pathway, potentially increasing their susceptibility to benzene’s toxic effects.^[1] Other enzymes, such as CYP2E1, are also involved in benzene metabolism, though common genetic variants in this region may not always show strong associations with SPMA levels.^[1]

Clinical Relevance

The of urinary SPMA holds significant clinical relevance for assessing individual and population-level benzene exposure. It serves as a non-invasive method for biomonitoring, particularly in occupational settings, among smokers, and in populations exposed to environmental benzene.^[1] Elevated SPMA levels indicate higher benzene uptake, which can inform risk assessments for benzene-related diseases, including certain cancers.^[1] Furthermore, understanding the influence of genetic factors, such as GSTT1 and GSTM1 polymorphisms, on SPMA levels allows for a more nuanced interpretation of exposure data, helping to identify individuals who may be more susceptible to benzene’s carcinogenicity despite similar measured SPMA levels.^[1] Studies have shown correlations between SPMA and other biomarkers of volatile carcinogens like total nicotine equivalents (TNE), total NNAL, 3-hydroxypropylmercapturic acid (3-HPMA), and 3-hydroxy-1-methylpropylmercapturic acid (HMPMA), suggesting its potential as a broader indicator of exposure to harmful substances in contexts like cigarette smoke.^[1]

Social Importance

From a public health perspective, the ability to accurately measure urinary SPMA is of considerable social importance. It enables researchers and policymakers to monitor population exposure to benzene, identify at-risk communities, and evaluate the effectiveness of public health interventions aimed at reducing exposure.^[1]The observed ethnic differences in SPMA levels and their correlation with lung cancer risk disparities highlight the importance of considering genetic and environmental factors in understanding health inequalities.^[1]For example, studies have shown varying SPMA levels across different ethnic groups, even after accounting for smoking habits and genetic variations, suggesting complex interactions that contribute to differential disease susceptibility.^[1] This understanding can guide targeted prevention strategies and contribute to more equitable health outcomes by addressing environmental justice concerns and personalized risk assessment.

Methodological and Statistical Power Constraints

The study, while the largest of its kind at the time, faced limitations in statistical power due to its sample size, particularly for a genome-wide association study (GWAS).^[1]With a total of 2,239 smokers, the research had 80% power to detect genetic factors explaining only 1.8% of the variation in urinary S-phenylmercapturic acid (SPMA) levels at a genome-wide significance threshold.^[1] This modest power implies that common genetic variants with smaller effects on SPMA levels may have been missed, limiting the comprehensiveness of genetic discovery.

Furthermore, the ethnic-specific sample sizes, ranging from 311 to 674 participants, restricted the ability to detect genetic variants explaining less than 6% to 11% of the variability in SPMA within any single ethnic group.^[1] Consequently, the study may not have identified less common alleles (with frequencies below 5%) or ethnic-specific variants that contribute to population differences in SPMA levels. Addressing these gaps will necessitate substantially larger studies tailored to specific racial and ethnic populations to uncover the full genetic landscape influencing SPMA.

Phenotypic and Interpretive Nuances

The interpretation of urinary SPMA levels is complicated by the dual influence of benzene exposure and genetic detoxification capacity, specifically involving the GSTT1 gene.^[1] While higher benzene exposure generally leads to increased SPMA, individuals with a GSTT1 null status, despite being at higher risk for benzene-induced toxicity, exhibit decreased SPMA levels.^[1] This “conundrum” presents a significant challenge for studies that lack GSTT1 genotyping information, as SPMA levels alone might not accurately reflect the internal benzene dose or the associated biological risk.

Additionally, phenotypic considerations, such as the variability in urine dilution, can influence SPMA results. Although adjusting for creatinine levels can mitigate some of these differences, it does not fully resolve all observed variability in SPMA across populations.^[1] While SPMA is a specific biomarker for benzene, its utility as a precise indicator of internal benzene dose and subsequent health effects is influenced by these genetic and physiological factors, underscoring the need for careful interpretation alongside relevant genetic and clinical data.

Unaccounted Variability and Remaining Knowledge Gaps

A significant portion of the variability in SPMA levels remains unexplained, even after accounting for various baseline covariates including age, sex, BMI, total nicotine equivalents, cigarettes per day, ethnicity, and principal components of genetic ancestry, which collectively explained only 37% of the total variance.^[1] This substantial unaccounted variability suggests that other unmeasured genetic factors, intricate gene-environment interactions, or additional environmental exposures play a critical role in determining SPMA levels. The lack of significant association found for previously reported CYP2E1 polymorphisms also highlights gaps in fully understanding the genetic architecture of benzene metabolism.^[1] Moreover, the study observed persistent and strong ethnic differences in SPMA levels even after adjusting for the powerful effects of GSTT1 and GSTM1 deletions.^[1]This indicates that other, as yet unidentified, genetic or environmental factors contribute to these population-specific disparities in benzene uptake and metabolism. Furthermore, while SPMA is a biomarker for benzene, a known cause of leukemia, its direct link to lung cancer etiology is less established in humans.^[1]The possibility that SPMA may serve as a biomarker for other volatile lung carcinogens in cigarette smoke suggests a broader, yet unconfirmed, role in cancer risk assessment that requires further investigation.^[1]

Variants

The genetic variant rs6003958 is situated in an intergenic region between the MIF-AS1 (Macrophage Migration Inhibitory Factor Antisense RNA 1) and KLHL5P1 (Kelch Like Family Member 5 Pseudogene 1) genes. This location suggests that rs6003958 may influence the regulatory activity of these nearby genes, potentially impacting their expression levels or the stability of their transcripts. Understanding such genetic influences is crucial for interpreting biomarkers like urinary S-phenylmercapturic acid (SPMA), which serves as a specific indicator of benzene uptake.^[1] Genome-wide association studies (GWAS) are instrumental in identifying common genetic variants that contribute to variations in SPMA levels across diverse populations.^[1] MIF-AS1 is categorized as a long non-coding RNA (lncRNA), which typically does not code for proteins but plays significant roles in regulating gene expression through various mechanisms, such as transcriptional interference, chromatin remodeling, or post-transcriptional control of messenger RNA. As an antisense RNA, MIF-AS1 may specifically regulate the expression of the MIF(Macrophage Migration Inhibitory Factor) gene, a key cytokine involved in immune responses, inflammation, and cellular proliferation. Variations inMIF-AS1 expression, potentially influenced by rs6003958 , could alter inflammatory pathways or cellular stress responses, which are broadly relevant to the body’s handling of environmental toxicants like benzene and could indirectly affect the levels of its metabolite, SPMA. Higher benzene exposure is known to lead to elevated levels of urinary SPMA.^[1] Adjacent to MIF-AS1 is KLHL5P1, a pseudogene, which is a DNA sequence resembling a functional gene but typically lacking protein-coding capacity due to mutations. Despite often being considered non-functional, some pseudogenes can exert regulatory influence, for instance, by acting as microRNA sponges or by producing their own non-coding RNAs that modulate the expression of their functional counterparts or other genes. The functional KLHL5 gene is involved in ubiquitination, a process critical for protein degradation and cellular quality control, which can be important in detoxification pathways. Therefore, rs6003958 might affect the expression or function of KLHL5P1, potentially impacting cellular responses to xenobiotics or contributing to the variability of SPMA levels, which are routinely analyzed using liquid chromatography-tandem mass spectrometry.^[1]

Key Variants

RS ID	Gene	Related Traits
rs6003958	MIF-AS1 - KLHL5P1	urinary S-phenylmercapturic acid

Definition and Metabolic Significance of S-Phenylmercapturic Acid

S-Phenylmercapturic acid (SPMA) is precisely defined as a specific urinary biomarker indicative of benzene uptake, serving as a critical metabolite formed during the detoxification of benzene in the body.^[1] Benzene, a ubiquitous environmental toxicant and carcinogen, undergoes metabolic transformation, and its conjugation with glutathione leads to the formation of mercapturic acids, with SPMA being the end-product of this pathway.^[1] The presence and concentration of SPMA in urine directly reflect an individual’s exposure to benzene, with higher benzene exposure correlating with elevated urinary SPMA levels.^[1] This conceptual framework positions SPMA as a valuable tool for assessing environmental or occupational benzene exposure, distinguishing it as a specific and reliable indicator.

SPMA’s significance extends beyond merely indicating benzene exposure; it also acts as a potential biomarker for other volatile carcinogens present in cigarette smoke.^[1] Studies have shown SPMA to be significantly correlated with other urinary biomarkers of exposure to tobacco toxicants, including total nicotine equivalents (TNE), total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), 3-hydroxypropylmercapturic acid (3-HPMA), and 3-hydroxy-1-methylpropylmercapturic acid (HMPMA).^[1] These correlations suggest that SPMA levels can offer insights into a broader spectrum of volatile toxicant uptake, making it a multifaceted tool in risk assessment for smoking-related diseases.

Analytical Methodologies and Operational Criteria

The precise quantification of urinary S-phenylmercapturic acid is typically achieved through advanced analytical techniques, primarily liquid chromatography-tandem mass spectrometry (LC-MS/MS).^[1] This method involves a rigorous process that includes the addition of an internal standard, such as [D5]SPMA, to urine samples to ensure accuracy and reproducibility.^[1] The analysis monitors specific mass spectrometry transitions (e.g., m/z 238.05 → m/z 109.05 for SPMA and m/z 243.05 → m/z 114.05 for [D5]SPMA) to accurately identify and quantify the compound.^[1] Operational definitions for SPMA concentration are typically expressed in picomoles per milliliter (pmol/ml) of urine, or sometimes adjusted for urinary creatinine levels (pmol/mg creatinine) to account for variations in urine dilution.^[1]These measurements are often further adjusted for confounding factors such as age, gender, body mass index (BMI), and total nicotine equivalents (TNE) to ensure robust comparisons across study populations.^[1] A defined limit of quantitation (LOQ), such as 0.1 pmol/ml, is established, with samples falling below this threshold typically excluded from analyses to maintain data quality.^[1]

Genetic and Ethnic Determinants of SPMA Levels

S-Phenylmercapturic acid levels exhibit significant variability influenced by both genetic predispositions and ethnic backgrounds, highlighting the complex interplay of metabolism and exposure.^[1] Genetic polymorphisms, particularly deletions in the Glutathione S-transferase T1 (GSTT1) and Glutathione S-transferase M1 (GSTM1) genes, are crucial determinants of SPMA concentrations.^[1] Specifically, individuals with the GSTT1 null genotype consistently show lower urinary SPMA levels compared to those who are GSTT1 positive when exposed to benzene, because the absence of the enzyme reduces the formation of the mercapturic acid conjugate.^[1] This genetic classification system significantly impacts the interpretation of SPMA levels, as GSTT1 deletion can account for a substantial portion (e.g., 14.2% to 31.6%) of the variability in SPMA levels among different populations.^[1] Beyond genetic factors, notable ethnic differences in mean SPMA levels have been observed, even after adjusting for smoking intensity and genetic variations.^[1] For instance, African Americans have demonstrated significantly higher SPMA levels compared to Whites, while Japanese Americans typically exhibit lower levels.^[1] These population-specific variations, observed when SPMA is expressed both per milliliter of urine and adjusted for creatinine, underscore the importance of considering ethnicity in research and clinical contexts.^[1]Such classifications are critical for understanding differential susceptibility to benzene toxicity and related health outcomes, including lung cancer risk, across diverse populations.^[1]

Benzene Metabolism and the Formation of S-Phenylmercapturic Acid (SPMA)

Urinary S-phenylmercapturic acid (SPMA) serves as a specific biomarker for benzene exposure. Benzene, a known human carcinogen and a cause of acute myeloid leukemia, requires metabolic activation to exert its toxic effects.^[1] This activation process involves the formation of benzene oxide, a critical intermediate in benzene carcinogenesis. To mitigate its harmful effects, benzene oxide undergoes detoxification primarily through conjugation with glutathione, a process catalyzed by a family of enzymes known as Glutathione S-transferases (GSTs), particularly GSTT1 and GSTM1.^[1] This glutathione conjugate is then further processed by a series of enzymatic reactions within the body, ultimately leading to the formation of SPMA, which is subsequently excreted in urine.^[1] The primary non-occupational source of benzene exposure is cigarette smoking, with a single cigarette containing 15–59 micrograms of benzene, accounting for nearly 90% of a smoker’s benzene exposure.^[1] The of urinary SPMA provides a reliable indicator of the body’s uptake of benzene. Studies have shown that when smokers cease smoking, their urinary SPMA levels rapidly decrease, often by approximately 80%, highlighting the direct link between active smoking and benzene exposure.^[1] Although CYP2E1 is recognized for its role in benzene metabolism, research indicates that common genetic variations in this gene may not significantly influence SPMA levels.^[1]

Genetic Determinants of Benzene Detoxification

Genetic variations in detoxification enzymes play a substantial role in individual differences in benzene metabolism and SPMA levels. Polymorphisms in Glutathione S-transferase genes, specifically deletions of the GSTT1 and GSTM1 genes, are significant factors.^[1] The GSTT1 gene deletion, which results in a non-functional enzyme, can account for a considerable portion of the variability in SPMA levels among smokers, explaining between 14.2% and 31.6% of the variance across different ethnic groups.^[1] Conversely, the GSTM1 deletion has a more modest impact, contributing between 0.2% and 2.4% to SPMA variability.^[1] The absence of a functional GSTT1 enzyme, known as the GSTT1 null status, directly affects the detoxification pathway of benzene oxide. Individuals with the GSTT1 null genotype exhibit lower urinary SPMA levels, despite potentially higher exposure to benzene oxide, because the primary pathway for forming the glutathione conjugate is impaired.^[1] This reduction in SPMA formation, however, suggests an increased availability of reactive benzene oxide, which can heighten the risk for benzene-induced toxicity and carcinogenicity.^[1] This inverse relationship between GSTT1 null status and SPMA levels underscores the importance of considering genetic background when interpreting SPMA as a biomarker of benzene exposure. In addition to GST genes, a genome-wide association study identified an imputed variant (rs110223001 ) at 1p13 associated with SPMA levels.^[1]

SPMA as a Biomarker of Carcinogen Exposure and Disease Risk

Urinary SPMA serves as a crucial biomarker for assessing individual exposure to benzene, a known human carcinogen linked to acute myeloid leukemia and acute non-lymphocytic leukemia.^[1] Beyond its direct link to benzene, SPMA levels have been found to correlate significantly with other urinary biomarkers of exposure to volatile toxicants and carcinogens found in cigarette smoke.^[1] These correlations include total nicotine equivalents (TNE), total NNAL (a biomarker for the tobacco-specific carcinogen NNK), 3-hydroxypropylmercapturic acid (3-HPMA) for acrolein, and 3-hydroxy-1-methylpropylmercapturic acid (HMPMA) for crotonaldehyde, with the strongest associations observed for TNE and total NNAL.^[1]Although benzene is not typically considered a primary cause of lung cancer in humans, the of SPMA can potentially serve as an indicator for uptake of other volatile carcinogens present in cigarette smoke that are implicated in lung cancer etiology.^[1] The utility of SPMA as a biomarker is complex, as higher benzene exposure directly leads to elevated SPMA levels, but genetic factors like GSTT1 null status can paradoxically result in lower SPMA despite increased carcinogenic risk.^[1] Therefore, comprehensive interpretation of SPMA levels requires consideration of both exposure levels and an individual’s genetic detoxification capacity.

Ethnic Variability in Benzene Metabolism and SPMA Levels

Significant differences in urinary SPMA levels have been observed across various ethnic populations, even after accounting for smoking intensity and other covariates.^[1] For instance, African Americans exhibit approximately 38% higher mean SPMA levels compared to Whites, while Japanese Americans show about 38% lower levels.^[1] These disparities persist even after adjusting for the powerful effects of GSTT1 and GSTM1 gene deletions, suggesting other genetic or environmental factors contribute to the observed ethnic differences.^[1] The prevalence of the GSTT1 null genotype, which significantly impacts SPMA formation, varies considerably among ethnic groups, with Japanese Americans and Native Hawaiians having higher null frequencies (66% and 51%, respectively) compared to African Americans (21.8%) and Caucasians (20.4%).^[1]These ethnic differences in benzene uptake, as reflected by urinary SPMA, align with observed disparities in lung cancer risk within the Multiethnic Cohort. Specifically, African Americans and Native Hawaiians exhibit a higher lung cancer risk than Whites for the same quantity of cigarette smoking, whereas Latinos and Japanese Americans demonstrate lower susceptibility.^[1] This highlights the complex interplay between genetic predisposition, environmental exposures, and population-specific health outcomes.

Metabolic Biotransformation of Benzene to S-Phenylmercapturic Acid

The formation of urinary S-phenylmercapturic acid (SPMA) is a specific metabolic pathway for the detoxification and excretion of benzene, a volatile carcinogen frequently encountered in cigarette smoke.^[1] Benzene itself requires metabolic activation to initiate its carcinogenic effects, primarily through the formation of the critical intermediate, benzene oxide.^[1] This epoxide intermediate is then a substrate for subsequent detoxification steps where it reacts with glutathione, a process primarily catalyzed by glutathione S-transferases (GSTs).^[1] The resulting glutathione conjugate of benzene oxide undergoes further enzymatic processing, including cleavage by gamma-glutamyl transpeptidase and dipeptidases, followed by N-acetylation, ultimately leading to the formation and urinary excretion of SPMA.^[1]

Genetic Regulation by Glutathione S-transferases

The efficiency of benzene detoxification and, consequently, SPMA formation is significantly influenced by genetic variations within the glutathione S-transferase gene family, particularly GSTT1 and GSTM1.^[1] Polymorphisms such as the deletion of the GSTT1 gene, resulting in a null genotype, dramatically reduce or eliminate the enzyme’s catalytic activity, thereby impairing the conjugation of benzene oxide with glutathione.^[1] This genetic status accounts for a substantial portion of the variability in SPMA levels in urine, with individuals carrying the GSTT1 null genotype exhibiting lower SPMA levels despite similar benzene exposure.^[1] A similar, though smaller, effect is observed with the GSTM1 deletion, highlighting how these gene regulations directly impact the metabolic flux through the mercapturic acid pathway.^[1]

Pathway Crosstalk and Integrated Toxicant Response

The metabolic pathways leading to SPMA production do not operate in isolation but are integrated within a broader network of toxicant responses, as evidenced by correlations with other urinary biomarkers of exposure.^[1] SPMA levels show significant correlations with total nicotine equivalents (TNE), total NNAL (a biomarker for a tobacco-specific carcinogen), 3-hydroxypropylmercapturic acid (3-HPMA, a biomarker for acrolein), and HMPMA (a biomarker for crotonaldehyde).^[1] These correlations suggest a degree of pathway crosstalk or co-regulation, where exposure to a complex mixture of toxicants, such as cigarette smoke, activates or influences multiple detoxification systems simultaneously.^[1] This systems-level integration indicates that SPMA may serve not only as a specific biomarker for benzene but also as an indicator of overall exposure to other volatile carcinogens and toxicants present in cigarette smoke.^[1]

Population-Level Determinants and Clinical Significance

The pathways and mechanisms governing SPMA levels exhibit significant variations across different populations, reflecting both environmental exposure differences and underlying genetic predispositions.^[1] For instance, African Americans demonstrate higher SPMA levels compared to Whites, while Japanese Americans show significantly lower levels, even after accounting for factors like total nicotine equivalents.^[1] These ethnic disparities are partly explained by differences in the prevalence of GSTT1 and GSTM1 null genotypes, which directly modulate the efficiency of benzene detoxification.^[1]Understanding these population-specific regulatory mechanisms is crucial for accurately interpreting SPMA as a biomarker for benzene uptake and its potential role in disease-relevant mechanisms, particularly given the “conundrum” thatGSTT1 null status, while reducing SPMA, may increase susceptibility to benzene’s toxic and carcinogenic effects due to higher availability of the reactive benzene oxide.^[1]

Clinical Relevance

The of urinary S-phenylmercapturic acid (SPMA) holds significant clinical relevance as a specific biomarker for benzene uptake, a known human carcinogen. Its utility extends across various facets of patient care, from assessing exposure and stratifying risk to informing personalized prevention strategies, particularly within populations exposed to tobacco smoke.

Assessment of Carcinogen Exposure and Risk

Urinary SPMA serves as a robust and specific indicator of benzene exposure, a critical factor given benzene’s classification as a human carcinogen responsible for acute myeloid leukemia and acute non-lymphocytic leukemia.^[1] Research demonstrates that the highest consistent non-occupational exposure to benzene occurs in cigarette smokers, with approximately 90% of a smoker’s benzene exposure originating from cigarette smoke.^[1] Consequently, SPMA levels rapidly decrease by approximately 80% upon smoking cessation, highlighting its utility in monitoring the effectiveness of smoking cessation interventions and assessing ongoing exposure.^[1]Furthermore, SPMA significantly correlates with other urinary biomarkers of volatile toxicant and carcinogen uptake, such as total nicotine equivalents (TNE), total NNAL (a tobacco-specific carcinogen biomarker), 3-HPMA (acrolein biomarker), and HMPMA (crotonaldehyde biomarker), suggesting its broader potential as an indicator for exposure to a spectrum of volatile carcinogens beyond benzene alone, which may contribute to lung cancer etiology.^[1]

Genetic Determinants and Differential Susceptibility

The clinical interpretation of urinary SPMA is significantly enhanced by considering genetic factors and ethnic variability, which play a crucial role in benzene metabolism and individual susceptibility. Studies have revealed substantial ethnic differences in SPMA levels, with African Americans exhibiting significantly higher levels and Japanese Americans significantly lower levels compared to Whites, even after accounting for smoking intensity and other covariates.^[1]These ethnic disparities in benzene uptake, as reflected by SPMA, align with observed differences in lung cancer risk within the Multiethnic Cohort.^[1] Genetic variations, particularly deletions in glutathione S-transferase T1 (GSTT1) and GSTM1 genes, profoundly influence SPMA levels, with the GSTT1 deletion accounting for a substantial portion of the variance.^[1] While higher benzene exposure generally leads to higher SPMA, individuals with a GSTT1 null status, which impairs benzene detoxification and theoretically increases carcinogenicity risk, paradoxically exhibit lower SPMA levels.^[1] This “conundrum” underscores the necessity of integrating genetic information with biomarker measurements for accurate risk stratification and personalized assessment of benzene-induced toxicity.^[1]

Informing Prognosis and Personalized Interventions

Integrating urinary SPMA measurements with genetic insights offers a powerful approach to predicting outcomes and tailoring interventions for individuals at risk of benzene-related health complications. By identifying individuals with higher benzene uptake or altered metabolic capacity due to genetic polymorphisms like GSTT1deletion, clinicians can better stratify risk for conditions such as leukemia and potentially lung cancer.^[1] For instance, understanding a patient’s GSTT1 status in conjunction with their SPMA levels can guide personalized prevention strategies, such as more intensive counseling for smoking cessation or enhanced surveillance for high-risk populations. This comprehensive approach moves beyond simple exposure assessment to incorporate individual biological responses, thereby supporting more precise prognostic evaluations and facilitating the development of targeted, personalized medicine strategies to mitigate long-term health implications.^[1]

Frequently Asked Questions About Urinary S Phenylmercapturic Acid

These questions address the most important and specific aspects of urinary s phenylmercapturic acid based on current genetic research.

---

1. If my urine test shows low levels of this chemical, am I safe from pollution?

Not necessarily. While lower levels usually mean less exposure, some people have genetic variations, like a deletion in the GSTT1 gene, that make their bodies less efficient at processing and excreting this chemical. This means you might actually have higher exposure and risk, even with lower measured levels, because your body isn’t clearing it as effectively.

2. Could my family’s background make me more sensitive to what I breathe in?

Yes, your family’s background can play a role. Genetic variations, particularly in genes like GSTT1 and GSTM1, affect how well your body detoxifies harmful chemicals from the environment. Different ethnic groups can have varying frequencies of these genetic variations, which might influence your individual susceptibility.

3. I don’t smoke, but I live near a busy road. Am I still at risk?

Yes, you can still be at risk. Benzene, the harmful chemical this test measures, is present in vehicle exhaust and is a common environmental pollutant. Even if you don’t smoke, exposure from living near busy roads or industrial areas can contribute to your overall body burden and potential health risks.

4. Why might my friend handle air pollution better than me, even if we’re exposed similarly?

It’s likely due to differences in your genetic makeup. Enzymes like Glutathione S-transferase (GSTs), particularly those from the GSTT1 and GSTM1 genes, are crucial for detoxifying harmful chemicals. Variations in these genes can make some individuals more efficient at processing pollutants, leading to different internal doses and health outcomes despite similar external exposure.

5. Does being around people who smoke affect my body’s chemical levels?

Absolutely. Tobacco smoke is a significant source of benzene. Being exposed to secondhand smoke means you are absorbing this chemical, which your body then processes. This exposure would likely be reflected in higher levels of S-phenylmercapturic acid in your urine, indicating an internal dose.

6. What if I work in a job where I’m exposed to fumes a lot?

If your job involves frequent exposure to fumes, especially from industrial sources or vehicle exhaust, you could be taking in more benzene. This is often used in occupational settings to monitor exposure and assess risk, as higher levels indicate greater uptake of this harmful chemical.

7. My doctor suggested this test; what does it really tell them about my health?

This urine test measures S-phenylmercapturic acid, which is a specific marker for benzene exposure. It helps your doctor understand how much benzene your body has absorbed, which is important because benzene is linked to serious health issues like leukemia and can inform risk assessments for certain cancers.

8. If I quit smoking, will my risk from these chemicals go down quickly?

Yes, quitting smoking will significantly reduce your exposure to benzene, and consequently, the levels of this chemical in your urine should decrease. This reduction in exposure is a crucial step in lowering your risk for benzene-related health problems, including certain cancers.

9. Could my ethnicity affect how my body deals with pollution?

Yes, studies have shown that there can be ethnic differences in how people process and excrete environmental pollutants like benzene. These differences can be partly due to varying frequencies of certain genetic variations that influence detoxification pathways, highlighting the importance of personalized risk assessment based on your background.

10. Does drinking a lot of water before my test change the results?

Yes, how much water you drink can influence the concentration of the chemical in your urine. While adjustments for urine dilution (like using creatinine levels) are often made, extreme hydration or dehydration can still affect the precise . It’s best to follow any specific instructions given for your test to ensure accurate results.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Haiman, Christopher A., et al. “Benzene Uptake and Glutathione S-transferase T1 Status as Determinants of S-Phenylmercapturic Acid in Cigarette Smokers in the Multiethnic Cohort.” PLoS One, vol. 11, no. 3, 2016, e0150641.